



Journal of **COMMERCIAL BIOTECHNOLOGY**

JULY 2013

VOLUME 19 | NUMBER 3

ISSN: 1462-8732 / eISSN 1478-565X

WWW.COMMERCIALBIOTECHNOLOGY.COM

Journal of COMMERCIAL BIOTECHNOLOGY

VOLUME 19

NUMBER 3

JULY 2013

Contents

Patenting human genes and mutations: A personal perspective <i>Ananda Mohan Chakrabarty</i>	3
The polyvalent scientist: The added value of management training <i>Maria Theodosiou, Arsia Amir-Aslani</i>	6
A role for virtual biotechnology companies in drug discovery and development? <i>Dianne Nicol, Johnathon Liddicoat, Christine Critchley</i>	10
The role of specialization in mutual fund investment strategies: An exploratory study of the life sciences industry <i>Osne Frans Kirzner, Lorraine Uhlaner</i>	20
Culture and the principles of biomedical ethics <i>Kola Abimbola</i>	34
Patent licensing considerations for biologics under the BPCIA <i>Sheila Swaroop, Carol Pitzel Cruz</i>	43
The relevance and importance of business development and licensing in the biopharmaceutical industry <i>Roger Davies</i>	49
Evergreening patents: The Indian Supreme Court rejects patenting of incremental improvements <i>Joanna T. Brougher</i>	57
The life sciences industry and the changing IP landscape <i>Dr Gareth Williams</i>	62
EU Legal & Regulatory Update — May 2013	69
Book review: The crowdfunding revolution: how to raise venture capital using social media <i>Steven S. Ma</i>	76

While every effort is made to see that no inaccurate data, opinion or statement appears in this journal, the Publishers and the Editors wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor(s) or advertiser(s) concerned. Accordingly, the Publishers, the Editors and their respective employees, officers and agents accept no liability whatsoever for the consequences of such inaccurate or misleading data, opinion or statement.